Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

Exclusion Criteria

• •1. Macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis, atrophy or dense subfoveal exudation involving the fovea in the study eye.
• •2. Significant APD or opacity of the refractive medium and miosis in the study eye that affect visual acuity or fundus examination.
• •3. Aphakia (except intraocular lens) or posterior capsular rupture of the lens in the study eye.
• •4. The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine.
• •5. MNV caused by non-nAMD exists in the study eye .
• •6. Active inflammation or infection in either eye before randomization.
• •7. Known allergy to any component of the study intervention or history of allergy to fluorescein or indocyanine green, any anesthetics or antimicrobial agents used during the course of the study.
• •8. Abnormal liver and kidney function.
• •9. Poorly-controlled blood pressure before randomization.
• •10. History of a cardiovascular and cerebrovascular events, including myocardial infarction, unstable angina pectoris, cerebrovascular accidents (including TIA), other thromboembolic diseases (such as thromboembolic angiitis, etc) within 6 months before randomization.
• •11. Evidence of significant uncontrolled concomitant diseases.
• •12. Participated in any drug (other than vitamins and minerals) or device clinical trials within 3 months or the duration of 5 half-lives of the study drug (which is longer) before randomization and have used the test drug or received device treatment.
• •13. Pregnant, lactating women who can not take contraceptive measures during the trial.